Statins as a newly recognized type of immunomodulator

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Statins (HMG-CoA reductase inhibitors) are widely used lipid-lowering drugs.
• Their role in immune response modulation was previously unestablished, despite some clinical observations.
• Major histocompatibility complex class II (MHC-II) molecules are crucial for T-lymphocyte activation and immune response control.

Purpose of the Study:

• To investigate the potential immunomodulatory effects of statins.
• To determine if statins influence the expression of MHC-II molecules.
• To explore the mechanism by which statins might affect immune responses.

Main Methods:

• Studied the effect of statins on interferon-gamma (IFN-gamma)-induced MHC-II expression.
• Examined the impact of statins on the transactivator CIITA and its inducible promoter IV.
• Utilized primary human endothelial cells (ECs) and monocyte-macrophages (Mphi) for experiments.

Main Results:

• Statins directly inhibit the IFN-gamma-induced upregulation of MHC-II expression.
• This inhibition is mediated by blocking the inducible promoter IV of the CIITA transactivator.
• The effect is specific to inducible MHC-II expression, not affecting constitutive expression.

Conclusions:

• Statins act as novel immunosuppressors by inhibiting inducible MHC-II expression and T-cell activation.
• This provides a scientific basis for using statins in organ transplantation and other immune-related pathologies.
• Statins offer a new avenue for immunomodulation beyond their lipid-lowering properties.